@article{1e47a7792be74af0bf40caafb07dcab2,
title = "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study",
author = "Barbara Pro and Ranjana Advani and Pauline Brice and Bartlett, \{Nancy L.\} and Rosenblatt, \{Joseph D.\} and Tim Illidge and Jeffrey Matous and Radhakrishnan Ramchandren and Michelle Fanale and Connors, \{Joseph M.\} and Yin Yang and Sievers, \{Eric L.\} and Kennedy, \{Dana A.\} and Andrei Shustov",
note = "Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL.",
year = "2012",
month = jun,
day = "20",
doi = "10.1200/JCO.2011.38.0402",
language = "American English",
volume = "30",
journal = "Journal of Clinical Oncology",
number = "18",
}